Efficacy of Fluoroscopic Guided Atlantoaxial Joint Injection on Head and Neck Pain and Sleep Quality in RA Patients

Status

UNKNOWN

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03606707

Enrollment

Registered

2018-07-31

Start date

2018-06-01

Completion date

2018-08-01

Last updated

2018-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Head, Sleep Disturbance

Brief summary

Efficacy of intra-articular steroid injection for inflamed atlantoaxial joint in patients with rheumatoid arthritis Inclusion criteria Patients with rheumatoid arthritis with MRI findings of atlantoaxial joint inflammation and failure of resolution after 2 weeks systemic steroid administration Exclusion criteria Coagulopathy, allergy to contrast material, pregnancy Interventional group (AS) group, received intra-articular steroid injection for atlantoaxial joint. , in addition to methotrexate and chloroquine 400 mg per day.

Detailed description

Efficacy of intra-articular steroid injection for inflamed atlantoaxial joint on sleep quality and head and neck pain in patients with rheumatoid arthritis Inclusion criteria Patients with rheumatoid arthritis with MRI findings of atlantoaxial joint inflammation and failure of resolution after 2 weeks systemic steroid administration Interventional group (AS) group, received intra-articular steroid injection for atlantoaxial joint. , in addition to methotrexate and chloroquine 400 mg per day.

Interventions

DRUGSteroids

intra-articular steroid injection for atlantoaxial joint

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients with rheumatoid arthritis with MRI findings of atlantoaxial joint inflammation and failure of resolution after 2 weeks systemic steroid administration

Exclusion criteria

* Coagulopathy, allergy to contrast material, pregnancy

Design outcomes

Primary

Measure	Time frame	Description
neck pain	3 months	Visual analog scale 0-10

Secondary

Measure	Time frame	Description
neck disability	3 months	Oswestry Neck Pain Questionnaire 0-50
sleep quality	3 months	Pittsburgh sleep quality index

Countries

Egypt

Contacts

Primary ContactManal Hassanien, MD

manal_hassanien@yahoo.com01062679200

Backup ContactAbdelraheem Elawamy, MD

arawamyyy@yahoo.com01000032655

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026